0001193125-26-186924.txt : 20260428 0001193125-26-186924.hdr.sgml : 20260428 20260428160504 ACCESSION NUMBER: 0001193125-26-186924 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20260424 FILED AS OF DATE: 20260428 DATE AS OF CHANGE: 20260428 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hagler Mark Arnold CENTRAL INDEX KEY: 0002126029 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39173 FILM NUMBER: 26907559 MAIL ADDRESS: STREET 1: C/O NOVABRIDGE BIOSCIENCES STREET 2: 2440 RESEARCH BOULEVARD, SUITE 400 CITY: ROCKVILLE STATE: MD ZIP: 20850 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NovaBridge Biosciences CENTRAL INDEX KEY: 0001778016 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: SUITE 400, 2440 RESEARCH BLVD CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: (301) 670 2800 MAIL ADDRESS: STREET 1: SUITE 400, 2440 RESEARCH BLVD CITY: ROCKVILLE STATE: MD ZIP: 20850 FORMER COMPANY: FORMER CONFORMED NAME: I-Mab DATE OF NAME CHANGE: 20190528 4 1 ownership.xml 4 X0609 4 2026-04-24 0001778016 NovaBridge Biosciences NBP 0002126029 Hagler Mark Arnold false C/O NOVABRIDGE BIOSCIENCES, 2440 RESEARCH BOULEVARD, SUITE 400 ROCKVILLE MD 20850 false true false false See Remarks false Ordinary Shares 2026-04-24 4 P false 230000 2.51 A 230000 D The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer. The reported securities are represented by 100,000 ADSs. The price reported in Column 4 is a weighted average price. These ADSs were purchased in multiple transactions at prices ranging from $2.44 to $2.54, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. President and Chief Commercial Officer /s/ Xi-Yong (Sean) Fu as attorney-in-fact 2026-04-28